How Biotech Startups Use Synthetic Biology to Produce Rare Plant Compounds

Episode 50 of Biotech Business with Fexingo explores how startups are engineering microbes to produce rare plant compounds — like the cancer drug paclitaxel (Taxol) and the malaria treatment artemisinin — without harvesting endangered plants. Lucas and Luna break down the synthetic biology toolbox: metabolic pathway engineering, enzyme optimization, and fermentation scale-up. They discuss the case of Amyris, which famously produced artemisinic acid in yeast, and Antheia, a current startup using similar approaches for opioid precursors and neuroactive compounds. The hosts explain why this matters for drug security: many plant-derived medicines are threatened by overharvesting, climate change, and long supply chains. They also touch on the economic hurdle: fermentation costs versus field cultivation, and how continuous improvements in synthetic biology are closing the gap. The episode closes with a look ahead: could we eventually make any plant molecule on demand? A specific, numbers-driven conversation that gives listeners one concrete insight about the intersection of biology and manufacturing. #SyntheticBiology #Biotech #DrugDiscovery #PlantCompounds #Amyris #Antheia #Artemisinin #Paclitaxel #MetabolicEngineering #Fermentation #DrugSecurity #Business #Technology #FexingoBusiness #BusinessPodcast #BiotechBusiness #Startups #FDA Keep every episode free: buymeacoffee.com/fexingo